Wednesday, July 8, 2026

Drug profile · INN

conjugated estrogens/medroxyprogesterone acetate

conjugated estrogens/medroxyprogesterone acetate (PREMPRO/PREMPHASE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 5
Pipeline programs 74
News articles 0
Drug details — conjugated estrogens/medroxyprogesterone acetate
US status
approved
Class
Route
ORAL
Patents
5
Programs
74
Data quality
0.84

Quick answer

conjugated estrogens/medroxyprogesterone acetate (PREMPRO/PREMPHASE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN conjugated estrogens/medroxyprogesterone acetate
Brand PREMPRO/PREMPHASE
Route ORAL
Formulation TABLET

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. GO42909 Phase 3 · HOFFMANN-LA ROCHE · Relapsed/refractory follicular lymphoma
  2. Phase 1: Olanzapine Phase 3 · Shanghai Mental Health · Schizophrenia
  3. Phase 2; Low Dose MYOBLOC Phase 3 · SUPERNUS PHARMACEUTICALS · Spasticity
  4. Phase 2; Low Dose MYOBLOC (15,000 Units) Phase 3 · SUPERNUS PHARMACEUTICALS · Spasticity
  5. conjugated estrogens Phase 3 · Ultragenyx UK · Osteoporosis
  6. 2023/3668 Phase 2 · George Institute for · Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-lo
  7. CSET 2020/3187 Phase 2 · George Institute for · Adult patients with metastatic and/or unresectable Non-Small
  8. CSET N° 2020/3188 Phase 2 · George Institute for · Patients with hormone-receptor positive (HR+) and human epid

Related patents

  1. US 8865230

    Compositions and methods for treating parasitic infections

    Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. CA 2723411

    PROCEDE

    Expires Wed Nov 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. TW 200942531

    Crystal forms of a nitrocatechol

    Expires Thu Oct 11 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. WO 2009084970

    3-N-PHÉNYL-1,3,4-OXADIAZOLONES 5-O-SUBSTITUÉES POUR UNE UTILISATION MÉDICALE

    Expires Wed Jul 04 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 7148193

    Compounds that bind to growth hormone receptor

    Expires Mon Dec 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is conjugated estrogens/medroxyprogesterone acetate?

conjugated estrogens/medroxyprogesterone acetate (PREMPRO/PREMPHASE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for conjugated estrogens/medroxyprogesterone acetate?

PREMPRO/PREMPHASE is a marketed brand name for conjugated estrogens/medroxyprogesterone acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of conjugated estrogens/medroxyprogesterone acetate?

conjugated estrogens/medroxyprogesterone acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.